Search

Your search keyword '"Erb, Holger Hans Hermann"' showing total 2 results
Start Over Author "Erb, Holger Hans Hermann"
2 results on '"Erb, Holger Hans Hermann"'

1. PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target

Author

Erb, Holger Hans Hermann, Ebert, Marlies, Kuhn, Ronja, Donix, Lukas, Haferkamp, Axel, Seed, Robert Ian, and Jüngel, Eva

Subjects
Cell Viability Testing, Urologic Neoplasms, Science, Cancer Treatment, DNA repair, Antineoplastic Agents, Research and Analysis Methods, Transfection, Biochemistry, Genetics, Gene Expression and Vector Techniques, Medicine and Health Sciences, Tumor Cells, Cultured, Humans, Small interfering RNAs, Non-coding RNA, Molecular Biology Techniques, Molecular Biology, Cell Analysis, Tumor Stem Cell Assay, Cell Proliferation, Molecular Biology Assays and Analysis Techniques, Biology and life sciences, Proteins, DNA, Prognosis, Protein Inhibitors of Activated STAT, SUMOylation, Gene regulation, Nucleic acids, Gene Expression Regulation, Neoplastic, Survival Rate, Bioassays and Physiological Analysis, Oncology, Small Ubiquitin-Related Modifier Proteins, Medicine, RNA, Hyperexpression Techniques, DNA damage, Gene expression, Post-translational modification, Cisplatin, Neoplasm Recurrence, Local, Research Article
Abstract

Urothelial cancer (UC) is one of the most common cancers in Europe and is also one of the costliest to treat. When first line therapies show initial success, around 50% of cancers relapse and proceed to metastasis. In this study we assessed the Protein inhibitor of activated signal transducers and activators of transcription (PIAS)1 as a potential therapeutic target in urothelial cancer. PIAS1 is a key regulator of STAT1 signalling and may be implicated in carcinogenesis. In contrast to other cancer types PIAS1 protein expression is not significantly different in malignant areas of UC specimens compared to non-malignant tissue. In addition, we found that down-regulation and overexpression of PIAS1 had no effect on the viability or colony forming ability of tested cell lines. Whilst other studies of PIAS1 suggest an important biological role in cancer, this study shows that PIAS1 has no influence on reducing the cytotoxic effects of Cisplatin or cell recovery after DNA damage induced by irradiation. Taken together, these in vitro data demonstrate that PIAS1 is not a promising therapeutic target in UC cancer as previously shown in different entities such as prostate cancer (PCa).

Published
2019

2. Relevance of the natural HDAC inhibitor sulforaphane as a chemopreventive agent in urologic tumors

Author

Jüngel, Eva, Erb, Holger Hans Hermann, Haferkamp, Axel, Rutz, Jochen, Chun, Felix, Blaheta, Roman A., Jüngel, Eva, Erb, Holger Hans Hermann, Haferkamp, Axel, Rutz, Jochen, Chun, Felix, and Blaheta, Roman A.

Abstract

Due to an increased understanding of molecular biology and the genomics of cancer, new and potent agents have been approved by the Food and Drug Administration (FDA) to fight this disease. However, all of these drugs cause severe side effects and resistance inevitably develops, re-activating tumor growth and dissemination. For this reason, patients turn to natural compounds as alternative or complementary treatment options, since it has been found that natural plant products may block, inhibit, or reverse cancer development. The present review focusses on the role of the natural compound sulforaphane (SFN) as an anti-tumor agent in urologic cancer. SFN is a natural compound found in cruciferous vegetables from the Brassicaceae family such as broccoli, cauliflower and cabbage. Several epidemiologic and clinical studies have documented chemopreventive properties of SFN, making it an interesting candidate for additive cancer treatment. SFN shows remarkable anti-tumor effects in vitro and in vivo without exerting toxicity. The review summarizes the current understanding of SFN and provides insights into its molecular mode of action with particular emphasis on epigenetic tumor control.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results